Remove 2022 Remove Networking Remove Pharmaceutical manufacturing
article thumbnail

Eli Lilly promises additional $1.6b manufacturing investment

European Pharmaceutical Review

billion and another 200 new jobs is planned for Eli Lilly and Company’s two new pharmaceutical manufacturing sites in Boone County, US. Eli Lilly’s investment here is the largest manufacturing investment at a single location in its history. Students will also be able to access a smart manufacturing lab.

article thumbnail

What factors are driving life sciences FDI in 2022?

Pharmaceutical Technology

FDI experts at Investment Monitor have highlighted the following list of factors as most important to life sciences companies considering a greenfield investment in 2022: labour, education, industry clusters, domestic market, infrastructure, business environment, costs and quality of life. appeared first on Pharmaceutical Technology.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Bob Harrell

Pharma Marketing Network

Bob is a life sciences and technology marketing leader with more than 25 years of experience working directly for pharmaceutical manufacturers (Merck, AstraZeneca, and Shire) and for technology companies that serve the industry (Appature, IQVIA, and Sparta). The post Bob Harrell appeared first on Pharma Marketing Network.

article thumbnail

Vaccine producers promise equal access in future pandemics

European Pharmaceutical Review

Three trade bodies representing vaccine creators and manufacturers are endorsing The Berlin Declaration framework , a proposal that outlines how the industry would reserve an allocation of real-time vaccine production for swift distribution to priority populations in lower-income countries in future pandemics.

article thumbnail

Call to arms as UK falls back in medicines manufacturing

pharmaphorum

Its report points to some positive developments under the umbrella of the UK’s Life Sciences Vision (LSV) programme, including £20 million in grant funding for medicines manufacturing investments in the 2020 single-year ending review, and the £60 million Life Sciences Innovative Manufacturing Fund (LSIMF) announced in March 2022.

article thumbnail

Tackling fake pharmaceuticals: an industry united against counterfeit products

European Pharmaceutical Review

Consequently, pharmaceutical manufacturers risk their reputation if impersonating products fail to deliver the expected quality or health impact. Criminal networks are penetrating established digital and ecommerce channels, benefitting from their trusted authenticity and authority to distribute fake products to unsuspecting patients.

article thumbnail

Strategies for Combination Therapy in Oncology: Part One – Business as Usual

PM360

Combination Therapy in Oncology Combination therapies comprising two or more therapeutic agents have become a cornerstone of oncology management and are increasingly a development focus for the pharmaceutical industry. JAMA Network Open 5 , no. 3 (2022): e222265. Between May 1, 2016, and May 31, 2021, 42% of all U.S. 2022.2265.